In CML, BCR-ABL, with its constitutive tyrosine kinase activity, stimulates multiple signalling pathways such as PI3K/AKT and MAPK/ERK. Here, AKT1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.